Somewhat Positive News Coverage Somewhat Unlikely to Affect Fate Therapeutics (FATE) Share Price

Media headlines about Fate Therapeutics (NASDAQ:FATE) have trended somewhat positive on Thursday, according to Accern. The research group rates the sentiment of media coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Fate Therapeutics earned a daily sentiment score of 0.18 on Accern’s scale. Accern also assigned news stories about the biopharmaceutical company an impact score of 46.1332483357432 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.

These are some of the media headlines that may have impacted Accern Sentiment Analysis’s scoring:

Several research firms have recently weighed in on FATE. ValuEngine raised Fate Therapeutics from a “sell” rating to a “hold” rating in a report on Friday, February 2nd. BidaskClub raised Fate Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Tuesday, January 23rd. Zacks Investment Research downgraded Fate Therapeutics from a “buy” rating to a “hold” rating in a report on Monday, January 22nd. Wedbush reissued an “outperform” rating and issued a $7.00 price objective (down from $10.00) on shares of Fate Therapeutics in a report on Thursday, January 18th. Finally, Piper Jaffray Companies began coverage on Fate Therapeutics in a report on Monday, December 18th. They issued an “overweight” rating and a $10.00 price objective for the company. Two investment analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company. The company has a consensus rating of “Buy” and a consensus target price of $7.71.

Shares of Fate Therapeutics (NASDAQ FATE) opened at $10.59 on Thursday. The company has a current ratio of 7.21, a quick ratio of 7.21 and a debt-to-equity ratio of 0.32. Fate Therapeutics has a fifty-two week low of $2.52 and a fifty-two week high of $10.86. The firm has a market capitalization of $539.90, a price-to-earnings ratio of -11.15 and a beta of 2.00.

ILLEGAL ACTIVITY WARNING: “Somewhat Positive News Coverage Somewhat Unlikely to Affect Fate Therapeutics (FATE) Share Price” was first published by BBNS and is the property of of BBNS. If you are accessing this story on another site, it was copied illegally and republished in violation of US & international trademark & copyright law. The correct version of this story can be read at https://baseballnewssource.com/markets/somewhat-positive-news-coverage-somewhat-unlikely-to-affect-fate-therapeutics-fate-share-price/1900221.html.

About Fate Therapeutics

Fate Therapeutics, Inc (Fate Therapeutics) is a clinical-stage biopharmaceutical company. The Company is engaged in development of programmed cellular immunotherapies for cancer and immune disorders. The Company’s cell therapy pipeline consists of immuno-oncology programs, including cancer immunotherapies derived from engineered induced pluripotent cells, and immuno-regulatory programs, including hematopoietic cell immunotherapies for protecting the immune system of patients undergoing hematopoietic cell transplantation and for suppressing autoimmunity.

Insider Buying and Selling by Quarter for Fate Therapeutics (NASDAQ:FATE)

Receive News & Ratings for Fate Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fate Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Three-Way Trade Sends Souza to Diamondbacks and Drury to Yankees
Three-Way Trade Sends Souza to Diamondbacks and Drury to Yankees
Eric Hosmer Agrees to Eight-Year Deal with San Diego Padres
Eric Hosmer Agrees to Eight-Year Deal with San Diego Padres
Report: Eduardo Nunez and Red Sox Agree to Deal for One Year
Report: Eduardo Nunez and Red Sox Agree to Deal for One Year
Los Angeles Angels Plan to Use Shohei Ohtani in Six-Man Rotation
Los Angeles Angels Plan to Use Shohei Ohtani in Six-Man Rotation
Cubs Sign Free Agent Yu Darvish
Cubs Sign Free Agent Yu Darvish
Mother of Pittsburgh Pirates Player Elias Diaz Has Been Kidnapped
Mother of Pittsburgh Pirates Player Elias Diaz Has Been Kidnapped


Leave a Reply

 
© 2006-2018 BBNS.